Details
Stereochemistry | RACEMIC |
Molecular Formula | C19H20N2O3 |
Molecular Weight | 324.3737 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC1C(=O)N(N(C1=O)C2=CC=C(O)C=C2)C3=CC=CC=C3
InChI
InChIKey=HFHZKZSRXITVMK-UHFFFAOYSA-N
InChI=1S/C19H20N2O3/c1-2-3-9-17-18(23)20(14-7-5-4-6-8-14)21(19(17)24)15-10-12-16(22)13-11-15/h4-8,10-13,17,22H,2-3,9H2,1H3
Oxyphenbutazone is a non-steroidal anti-inflammatory drug, cyclooxygenase (prostaglandin synthetase) inhibitors which was marked under brand name tandearil for the treatment rheumatic disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis. But this drug was withdrawn from markets due to bone marrow suppression.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094253 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3108222 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | TANDEARIL Approved UseUnknown Launch Date-2.84947186E11 |
|||
Palliative | TANDEARIL Approved UseUnknown Launch Date-2.84947186E11 |
|||
Palliative | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
21.42 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10518246/ |
97.49 mg single, oral dose: 97.49 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYPHENBUTAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
12 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10518246/ |
94.99 mg single, oral dose: 94.99 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYPHENBUTAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
18.24 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10518246/ |
95.75 mg single, oral dose: 95.75 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYPHENBUTAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
24.05 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10518246/ |
98.82 mg single, oral dose: 98.82 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYPHENBUTAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
24.54 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10518246/ |
95.38 mg single, oral dose: 95.38 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYPHENBUTAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
397.401 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10518246/ |
97.49 mg single, oral dose: 97.49 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYPHENBUTAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
285.932 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10518246/ |
94.99 mg single, oral dose: 94.99 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYPHENBUTAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
381.688 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10518246/ |
95.75 mg single, oral dose: 95.75 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYPHENBUTAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
463.858 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10518246/ |
98.82 mg single, oral dose: 98.82 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYPHENBUTAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
482.606 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10518246/ |
95.38 mg single, oral dose: 95.38 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYPHENBUTAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
Doses
Dose | Population | Adverse events |
---|---|---|
800 mg 1 times / day multiple, oral Studied dose Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Sources: |
unhealthy, 31-72 years n = 66 Health Status: unhealthy Condition: gout Age Group: 31-72 years Sex: M+F Population Size: 66 Sources: |
|
200 mg 3 times / day multiple, oral Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: |
unhealthy, 48 years n = 1 Health Status: unhealthy Condition: progressive shoulder pain Age Group: 48 years Sex: F Population Size: 1 Sources: |
Disc. AE: Bone marrow granuloma... AEs leading to discontinuation/dose reduction: Bone marrow granuloma (1 patient) Sources: |
100 mg 2 times / day multiple, oral Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: |
unhealthy, 64 years n = 1 Health Status: unhealthy Condition: rheumatoid arthritis Age Group: 64 years Sex: F Population Size: 1 Sources: |
Disc. AE: Thrombocytopenic purpura... AEs leading to discontinuation/dose reduction: Thrombocytopenic purpura (1 patient) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Bone marrow granuloma | 1 patient Disc. AE |
200 mg 3 times / day multiple, oral Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: |
unhealthy, 48 years n = 1 Health Status: unhealthy Condition: progressive shoulder pain Age Group: 48 years Sex: F Population Size: 1 Sources: |
Thrombocytopenic purpura | 1 patient Disc. AE |
100 mg 2 times / day multiple, oral Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: |
unhealthy, 64 years n = 1 Health Status: unhealthy Condition: rheumatoid arthritis Age Group: 64 years Sex: F Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
[Inhibitory effect of oxyphenbutazone against Mycobacterium tuberculosis in vitro]. | 1969 Feb |
|
[Acute myelogenous leukemia. Associated with oxyphenbutazone induced aplastic anemia]. | 1974 Aug 10 |
|
Study of fatal bone marrow depression with special reference to phenylbutazone and oxyphenbutazone. | 1977 Jun 11 |
|
Drug-associated acute pancreatitis: twenty-one years of spontaneous reporting in The Netherlands. | 1999 Sep |
|
FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1. | 2013 Sep 5 |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6616956
It was investigated the possibility of oxyphenbutazone (OPh) inhibited the complement system and thus ameliorated the acute pathological changes induced by immune complexes. Treatment of fresh human serum with OPh inhibited both the classical and alternative complement (C) pathway activities in a dose-dependent fashion with a 50% inhibition dose 1.3 mg/ml. OPh was shown to form complexes with C5, thereby inhibiting the interaction between C3b and C5 and the cleavage of the latter into phlogistic fragments.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 16:05:22 UTC 2023 , Edited by admin on Fri Dec 15 16:05:22 UTC 2023
|
||
|
WHO-ATC |
M02AA04
Created by
admin on Fri Dec 15 16:05:22 UTC 2023 , Edited by admin on Fri Dec 15 16:05:22 UTC 2023
|
||
|
WHO-ATC |
S01BC02
Created by
admin on Fri Dec 15 16:05:22 UTC 2023 , Edited by admin on Fri Dec 15 16:05:22 UTC 2023
|
||
|
WHO-ATC |
M01AA03
Created by
admin on Fri Dec 15 16:05:22 UTC 2023 , Edited by admin on Fri Dec 15 16:05:22 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
76258
Created by
admin on Fri Dec 15 16:05:22 UTC 2023 , Edited by admin on Fri Dec 15 16:05:22 UTC 2023
|
PRIMARY | |||
|
SUB09572MIG
Created by
admin on Fri Dec 15 16:05:22 UTC 2023 , Edited by admin on Fri Dec 15 16:05:22 UTC 2023
|
PRIMARY | |||
|
4641
Created by
admin on Fri Dec 15 16:05:22 UTC 2023 , Edited by admin on Fri Dec 15 16:05:22 UTC 2023
|
PRIMARY | |||
|
76259
Created by
admin on Fri Dec 15 16:05:22 UTC 2023 , Edited by admin on Fri Dec 15 16:05:22 UTC 2023
|
PRIMARY | |||
|
3144
Created by
admin on Fri Dec 15 16:05:22 UTC 2023 , Edited by admin on Fri Dec 15 16:05:22 UTC 2023
|
PRIMARY | |||
|
DTXSID1045291
Created by
admin on Fri Dec 15 16:05:22 UTC 2023 , Edited by admin on Fri Dec 15 16:05:22 UTC 2023
|
PRIMARY | |||
|
Rapostan
Created by
admin on Fri Dec 15 16:05:22 UTC 2023 , Edited by admin on Fri Dec 15 16:05:22 UTC 2023
|
PRIMARY | |||
|
783
Created by
admin on Fri Dec 15 16:05:22 UTC 2023 , Edited by admin on Fri Dec 15 16:05:22 UTC 2023
|
PRIMARY | |||
|
m8341
Created by
admin on Fri Dec 15 16:05:22 UTC 2023 , Edited by admin on Fri Dec 15 16:05:22 UTC 2023
|
PRIMARY | Merck Index | ||
|
204-936-2
Created by
admin on Fri Dec 15 16:05:22 UTC 2023 , Edited by admin on Fri Dec 15 16:05:22 UTC 2023
|
PRIMARY | |||
|
129-20-4
Created by
admin on Fri Dec 15 16:05:22 UTC 2023 , Edited by admin on Fri Dec 15 16:05:22 UTC 2023
|
PRIMARY | |||
|
C74597
Created by
admin on Fri Dec 15 16:05:22 UTC 2023 , Edited by admin on Fri Dec 15 16:05:22 UTC 2023
|
PRIMARY | |||
|
A7D84513GV
Created by
admin on Fri Dec 15 16:05:22 UTC 2023 , Edited by admin on Fri Dec 15 16:05:22 UTC 2023
|
PRIMARY | |||
|
526053
Created by
admin on Fri Dec 15 16:05:22 UTC 2023 , Edited by admin on Fri Dec 15 16:05:22 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)